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Retrospective evaluation of venous
thromboembolism prophylaxis in the adult
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Chin Y Liu, PharmD

Study objectives. Hospitalized cancer patients are
at an increased risk for venous thromboembolism
(VTE) and it is recommended they receive pharmacologic prophylaxis unless otherwise contraindicated. The majority of data supporting this
recommendation comes from sub-group analyses
and extrapolation of data gathered in general
medical/surgical patients. This study seeks to
assess the safety and efficacy of VTE prophylaxis
in cancer patients admitted to our institution.
Methods. Charts of patients 18–89 years of age
receiving VTE prophylaxis with unfractionated
heparin, low molecular weigh heparin, or fondaparinux while admitted to Karmanos Cancer Center
between September and October 2007 were retrospectively reviewed. Risk factors for VTE were
assessed and the efficacy/safety of the prophylactic
agents was compared.
Results. One-hundred and eighty consecutive
patients were identified. The average number of
risk factors for developing VTE was 3–4 per hospital

BACKGROUND
Patients diagnosed with cancer are at an increased
risk for venous thromboembolism (VTE) and recurrent VTE has also been more frequently observed.1,2
In the hospitalized general medical/surgical population, the prevalence of VTE ranges from 10% to 40%.1
Cancer alone is associated with a 4-fold greater VTE
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admission in addition to an active cancer diagnosis.
Three VTEs occurred in the heparin group with two
patients experiencing a VTE during their admission
and one experiencing a VTE within 1 month after
discharge. Four (2.6%) patients receiving heparin
had a major bleeding event. Minor bleeding
occurred in 14.3, 11.5, and 22.2% of patients
receiving heparin, enoxaparin, and fondaparinux,
respectively.
Conclusions. This retrospective study showed
cancer patients are at increased risk for VTE,
typically with 3–4 risk factors per admission. VTEs
were uncommon; however, three patients receiving
heparin experienced a VTE and four had a major
bleeding event. Minor bleeding rates were similar
among groups. J Oncol Pharm Practice (2009)
00: 1–5.
Key words: venous thromboembolism; heparin; enoxaparin; fondaparinux; prophylaxis

risk compared to this general population, especially
among those receiving active therapy for their
malignancy.2 Additionally, cancer patients undergoing surgery have twice the risk for post-operative
deep venous thrombosis (DVT) and three times the
risk for pulmonary embolism (PE).1
Currently the American College of Chest Physicians
(ACCP), the American Society of Clinical Oncology
(ASCO), and the National Cancer Care Network
(NCCN) provide guidelines for the management and
prevention of VTE in cancer patients.1–3 Though
there are some differences in the identified risk
factors for VTE among these consensus guidelines,

ß 2009 SAGE Publications
Los Angeles, London, New Delhi and Singapore

Downloaded from opp.sagepub.com at BUTLER UNIV on July 28, 2016

10.1177/1078155209104379

[Ver: A3B2WIN8.07r/W-Standard]
REVISED PROOFS
Paper: OPP 104379

2

[6.4.2009–12:33pm]

[1–6]
(OPP)
SAGE

Reeves and Liu: VTE prophylaxis in the adult cancer patient

common risks agreed upon by all three include active
cancer, increased age, obesity, history of prior VTE,
heritable prothrombotic mutations, surgery, hospitalization/acute medical illness, chemotherapy, erythropoietic stimulating agents, and hormonal therapy.
Pharmacologic prophylaxis has been shown to
decrease the rate of VTE in various settings.1–3
Available prophylactic anticoagulants include unfractionated heparin (UFH), low molecular weight heparins (LMWH), and fondaparinux. All three available
guidelines currently recommend pharmacologic VTE
prophylaxis with one of the aforementioned agents in
cancer patients admitted to the hospital without
contraindications.1–3 This recommendation is largely
based on evidence and experience from the general
medical and surgical patients, as there is limited data
specifically evaluating the impact of such prophylactic
measures in cancer patients. The purpose of this study
was to retrospectively assess and compare the efficacy
and safety of VTE prophylaxis practices in the cancer
population admitted to our institution.

hospitalization and an assessment of the risk factors
patients possessed. Major bleeding was defined as
intracranial or retroperitoneal bleeding, bleeding
resulting in 42 g/dL drop in hemoglobin, or that
leading to transfusion or death. Minor bleeding was
also assessed and included all bleeding besides that
meeting criteria for major bleeding. Heparin-induced
thrombocytopenia (HIT) was defined according to
the following: a platelet drop to 5100,000/mm3 or
450% decline, inflammation and/or necrosis at the
heparin injection site, positive platelet factor 4
dependant immunoassay with clinical signs of HIT,
or development of new arterial or venous thrombotic
event with clinical signs of HIT.
ACCP, ASCO, and NCCN guidelines were utilized in
choosing risk factors to evaluate. Those appearing in
2 of the guidelines were chosen, and include: active
cancer, age 465, body mass index (BMI) 430 kg/m2,
prior VTE, heritable prothrombotic mutations, surgery, hospitalization/acute medical illness, infection,
lung disease, congestive heart failure, and receipt of
chemotherapy or hormonal therapy.

METHODS

Statistical analysis
Chi-squared and analysis of variance (ANOVA) was
utilized to compare continuous variables. Ordinal
data was compared with Kruskal–Wallis one-way analysis of variance. Statistical significance was defined as
a p-value 50.05. SPSS v10.0 (SPSS Incorporated,
Chicago, IL) statistical software was used to analyze
the data.
This study was approved by the Human
Investigation Committee at Wayne State University
and the Protocol Review and Monitoring Committee
at Karmanos Cancer Center.

Study population
Cancer patients admitted to our institution from
September to October 2007 receiving prophylactic
anticoagulants were identified by searching the
pharmacy’s electronic database. Patients were
excluded if they received prophylaxis for less than
1 day, if they were pregnant, were younger than 18 or
older than 89 years of age. Pharmacologic prophylactic agents utilized included UFH, enoxaparin, and
fondaparinux.
Data collection
Patients included in this study had both their electronic and paper-based medical record reviewed for
the duration of their hospital stay and for 4 weeks after
discharge. Data collection included demographic data,
risk factors for VTE development, symptomatic VTE,
major and minor bleeding, and laboratory results
(hemoglobin, platelets, serum creatinine).
Endpoints
The primary endpoint was to compare both the
symptomatic VTE rate during hospitalization and
within 4 weeks of hospital discharge between the
three prophylactic agents. VTE was defined as either
DVT or PE. Secondary endpoints included the safety
outcomes of the anticoagulants utilized during

RESULTS
Patients
One-hundred and eighty patients were identified and
included in the study. Heparin was the anticoagulant
used for 144 (80%), enoxaparin for 23 (13%),
fondaparinux for 9 (5%), and multiple agents for 4
(2%) patients. These patients accounted for 193
admissions within the 2-month period of time that
data collection occurred (154 (80%) heparin; 26 (13%)
enoxaparin; 9 (5%) fondaparinux; 4(2%) multiple
agents during hospital stay). The four patients who
had prophylactic drugs changed during their admission
were excluded from this analysis. Overall, baseline
characteristics were similar between groups (Table 1).
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Table 1.

Baseline characteristics

Table 2.

Heparin
n ¼ 144

Enoxaparin
n ¼ 23

Age (years)
Body mass
index (kg/m2) a
Length of stay (days)
Length of
prophylaxis (days)

57.7  13.7
25.9  6.6

Mean  SD
60.1  9.2
57.4  11.2
31.7  10.7 26.4  11.2

7.5  6.3
5.9  4.28

8.3  5.7
6.5  4.34

Male
Race
White
Black
Hispanic
Asian
Other
Unknown
Diagnosis
Myeloma
Lymphoma
Leukemia
Gastrointestinal
Breast
Thoracic/Head
& neck
Gynecological
Genitourinary
Other

71 (49.3)
71
64
1
2
1
5

(49.3)
(44.4)
(0.7)
(1.4)
(0.7)
(3.5)

3
10
4
31
15
44

(2.1)
(6.9)
(2.8)
(21.5)
(10.4)
(30.6)

8 (5.6)
11 (7.6)
18 (12.5)

No. of patients (%)
5 (21.7)
4 (44.4)
12 (52.2)
9 (39.1)

Risk factors for VTE development

Fondaparinux
n¼9

11.2  7.2
7.7  6.38

5 (55.6)
3 (33.3)
1 (11.1)

3

Heparin
n ¼ 154
Number of risk factors
(Mean  SD)

3.3  1.0

Risk factors
Obesity
Surgery
Age
CHF
Estrogen
Chemotherapy
Tamoxifen
Prior VTE
Infection
Lung disease

36 (23.4)
60 (39)
41 (26.6)
5 (3.2)
8 (5.2)
13 (8.4)
1 (0.6)
4 (2.6)
5 (3.2)
23 (14.9)

Enoxaparin
n ¼ 26

Fondaparinux
n¼9

3.8  1.0
3.3  1.3
No. of patients (%)
14 (53.8)
12 (46.2)
5 (19.2)
1 (3.8)
4 (15.4)

2
6
3
1

(22.2)
(6.7)
(33.3)
(11.1)

4 (15.4)
3 (11.5)
3 (11.5)

2 (8.7)

Endpoints
4 (17.4)

1 (11.1)
1 (11.1)

2 (8.7)

6 (66.7)

17 (73.9)
1 (11.1)

a

Bonferroni Correction: difference between heparin and enoxaparin groups
(p ¼ 0.002).

There was a statistical difference in body mass index
(p ¼ 0.003), which was determined to be between
the heparin and enoxaparin groups after Bonferroni
correction (p ¼ 0.002).
The majority of patients on heparin (80%)
received 5000 units subcutaneously every 8 h, and
84.6% of those on enoxaparin received 40 mg daily.
All patients in the fondaparinux group received
2.5 mg daily.
Risk factors for VTE
On an average, patients in the study had 3–4 risk
factors per hospital admission in addition to their
active cancer diagnosis. The most common risk
factors among the three prophylactic anticoagulant
groups included obesity (22.2–53.8%), surgery
(6.7–39%), and age 465 (19.2–33.3%) (Table 2).
A significant difference in the number of risk factors
was noted between the groups (p ¼ 0.037); however,
this difference was not present after Bonferroni
correction.

Venous thromboembolism events. Three symptomatic VTE events were experienced throughout
the study, including two while a patient was
admitted and one within 1 month of hospital
discharge. All were DVTs and no patients experienced a PE. No differences between groups in
the VTE rate were present; however, all VTEs
observed occurred in the heparin group (Table 3).
All patients who experienced a VTE were male with
an average of 3.33 risk factors. One patient with
nonsmall cell lung cancer developed a DVT within
3 days of hospital admission while on heparin 5000
units every 8 h. Another patient with pancreatic
cancer experienced two DVTs. The first event
occurred within 2 days of admission after starting
prophylactic heparin 5000 units every 8 h and
the second event occurred within 4 weeks from
discharge which was unrelated to the initial DVT. The
patient did not receive anticoagulant treatment
for the initial DVT based on an overall unfavorable
risk/benefit ratio.

Safety. Major and minor bleeding rates did not differ
between the groups; however, major bleeding was
only experienced by those on heparin (2.6%) and
included two gastrointestinal bleeding events and
one post-operative bleeding event and one patient
experienced hematemesis with 42 g/dL drop in
hemoglobin. All four experiencing a major bleed
required transfusion support. Bleeding rates (major
and minor) observed in these three groups were
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Table 3.

VTE events and bleeding
Heparin
n ¼ 154

Enoxaparin
n ¼ 26

Fondaparinux
n¼9

No. of patients (%)
VTE during admission
DVT
2 (1.3)
PE
0
VTE within 1 month of discharge
DVT
1 (0.6)
PE
0
Total VTE
DVT
3 (1.9)
PE
0
Major bleeding
4 (2.6)
Minor bleeding
22 (14.3)
Total bleeding
26 (16.9)

0
0

0
0

0
0

0
0

0
0
0
3 (11.5)
3 (11.5)

0
0
0
2 (22.2)
2 (22.2)

11.5–22.2% (Table 3). No patients experienced
heparin-induced thrombosis (HIT).

DISCUSSION
Despite the increased risk for VTE in cancer,
pharmacologic prophylaxis effectively prevented
VTEs in the study population. Overall, symptomatic
VTEs were uncommon (1.6%) in this retrospective
study and complications due to the prophylactic
anticoagulant were infrequent and manageable.
Minor bleeding was experienced by a reasonable
proportion of patients (14% of the total population),
and only 2.1% developed a major bleed while on
prophylactic anticoagulation.
Prophylactic anticoagulants have demonstrated
efficacy in other studies; however, in the cancer
population, this has largely consisted of subgroup
analyses. Of the entire medically ill population
enrolled in VTE prophylaxis trials, only 4.5–20.9%
were cancer patients.4–8 Despite this, pharmacologic
VTE prophylaxis has demonstrated efficacy, even in
this small subgroup. In the MEDENOX trial, the VTE
rate among cancer patients (n ¼ 72; 12.4% of enrolled
patients) was decreased from 19.5% in the placebo
group to 9.7% in the enoxaparin group.4 Another
study showed heparin 5000 units every 12 h was not
different from the control group in reducing the fatal
PE rate in a general medical population; however,
a meta-analysis has shown that heparin 5000 units
every 8 h was equivalent to LMWH in decreasing
DVTs.7,8 For this reason major guidelines recommend
heparin 5000 units every 8 h, which is consistent

with the dose the majority of the patients in this
analysis received.
More evidence is available to support the use of VTE
prophylaxis in the cancer population undergoing surgery.9–15 Heparin, enoxaparin, dalteparin, and fondaparinux have all been evaluated in this setting with
28–100% of the study population having a cancer
diagnosis.10–14 In the surgical setting, VTE rates among
those receiving prophylaxis ranges from 4.7 to 18%.10–14
The 1.6% VTE rate experienced in this study is lower
than that described in other studies, although the
present study only evaluated symptomatic VTEs.
The patients in the enoxaparin group in this study
differed from the other groups in that the majority of
these patients were gynecological oncology patients.
This is not surprising as many of these patients were
undergoing abdominal surgery and many of the
studies evaluating VTE prophylaxis in this setting
utilized a LMWH.11–15 Additionally, many of these
patients (53.8%) were obese. Limited evidence exists
on the adequate prophylactic dose of LMWH in the
obese population; however, given the lack of an
increase in VTEs in this group, the standard 40 mg
daily dose may be adequate. Nevertheless, this
subgroup is too small to draw any firm conclusions.
Though risk factors have been described in the
literature, to our knowledge no data is available on
the average risk level of patients with cancer. In the
general population, almost all hospitalized patients
have at least one risk factor for VTE development;
however, only 40% have 3 risk factors.1 Patients
included in this study had 3–4 major risk factors
for VTE per admission, and 79% had 3 risk factors
besides their active cancer diagnosis. This is significant and underscores the difference in risk between
the general and cancer populations. The increased
risk observed in this study highlights the importance
of VTE prophylaxis in the cancer population.
Moreover, 41.3% of the entire study population
underwent surgery without an increase in bleeding
with prophylactic anticoagulants. Prior studies have
documented major bleeding rates of 0.2–4.1% and
minor bleeding rates of 1–14.6% and bleeding rates
documented in this report (major: 2.1%; minor: 14%)
fall within these ranges.5,6,11–14
This study is limited by its size and the disparity in
size between groups. VTEs and major bleeding events
were only observed in the heparin group; however,
this may be a result of the size of the heparin group
compared to the other groups. Additionally, the
retrospective nature of this project limits the conclusions, which can be drawn from the data. It is possible
that all bleeding events may not have been

J Oncol Pharm Practice, Vol 00: No 00, 2009

Downloaded from opp.sagepub.com at BUTLER UNIV on July 28, 2016

[Ver: A3B2WIN8.07r/W-Standard]
REVISED PROOFS
Paper: OPP 104379

[6.4.2009–12:33pm]

[1–6]
(OPP)
SAGE

Reeves and Liu: VTE prophylaxis in the adult cancer patient

documented in the patients’ charts, which may be
particularly true in tracking minor bleeding. Despite
this, bleeding rates were similar between groups.
The 1-month VTE rate may also be underestimated,
as these events may not have been documented
in the medical record, especially if the patient
presented to another facility outside of our health
care system.
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CONCLUSION
The majority of patients in this study received
heparin prophylaxis; however, gynecological oncology patients were more likely to receive enoxaparin,
which may be due to the number of intra-abdominal
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